Wang Ke, Li Ling, Fu Liang, Yuan Yongqiang, Dai Hongying, Zhu Tianjin, Zhou Yuxi, Yuan Fang
Clinical Laboratory, Yongchuan People's Hospital of Chongqing, Chongqing, China.
Clinical Laboratory, Yongchuan Hospital of Chongqing Medical University, Chongqing, China.
Front Pharmacol. 2019 Mar 1;10:140. doi: 10.3389/fphar.2019.00140. eCollection 2019.
Breast cancer is one of the leading causes of death among women. RNA binding proteins (RBPs) play a vital role in the progression of many cancers. Functional investigation of RBPs may contribute to elucidating the mechanisms underlying tumor initiation, progression, and invasion, therefore providing novel insights into future diagnosis, treatment, and prognosis. We downloaded RNA sequencing data from the cancer genome atlas (TCGA) by UCSC Xena and identified relevant RBPs through an integrated bioinformatics analysis. We then analyzed biological processes of differentially expressed genes (DEGs) by DAVID, and established their interaction networks and performed pathway analysis through the STRING database to uncover potential biological effects of these RBPs. We also explored the relationship between these RBPs and the prognosis of breast cancer patients. In the present study, we obtained 1092 breast tumor samples and 113 normal controls. After data analysis, we identified 90 upregulated and 115 downregulated RBPs in breast cancer. GO and KEGG pathway analysis indicated that these significantly changed genes were mainly involved in RNA processing, splicing, localization and RNA silencing, DNA transposition regulation and methylation, alkylation, mitochondrial gene expression, and transcription regulation. In addition, some RBPs were related to histone H3K27 methylation, estrogen response, inflammatory mediators, and translation regulation. Our study also identified five RBPs associated with breast cancer prognosis. Survival analysis found that overexpression of DCAF13, EZR, and MRPL13 showed worse survival, but overexpression of APOBEC3C and EIF4E3 showed better survival. In conclusion, we identified key RBPs of breast cancer through comprehensive bioinformatics analysis. These RBPs were involved in a variety of biological and molecular pathways in breast cancer. Furthermore, we identified five RBPs as a potential prognostic biomarker of breast cancer. Our study provided novel insights to understand breast cancer at a molecular level.
乳腺癌是女性死亡的主要原因之一。RNA结合蛋白(RBPs)在多种癌症的进展中起着至关重要的作用。对RBPs的功能研究可能有助于阐明肿瘤发生、进展和侵袭的潜在机制,从而为未来的诊断、治疗和预后提供新的见解。我们通过UCSC Xena从癌症基因组图谱(TCGA)下载了RNA测序数据,并通过综合生物信息学分析确定了相关的RBPs。然后,我们使用DAVID分析差异表达基因(DEGs)的生物学过程,并通过STRING数据库建立它们的相互作用网络并进行通路分析,以揭示这些RBPs的潜在生物学效应。我们还探讨了这些RBPs与乳腺癌患者预后之间的关系。在本研究中,我们获得了1092个乳腺肿瘤样本和113个正常对照。经过数据分析,我们在乳腺癌中鉴定出90个上调的RBPs和115个下调的RBPs。GO和KEGG通路分析表明,这些显著变化的基因主要参与RNA加工、剪接、定位和RNA沉默、DNA转座调控和甲基化、烷基化、线粒体基因表达和转录调控。此外,一些RBPs与组蛋白H3K27甲基化、雌激素反应、炎症介质和翻译调控有关。我们的研究还鉴定出五个与乳腺癌预后相关的RBPs。生存分析发现,DCAF13、EZR和MRPL13的过表达显示出较差的生存率,但APOBEC3C和EIF4E3的过表达显示出较好的生存率。总之,我们通过综合生物信息学分析确定了乳腺癌的关键RBPs。这些RBPs参与了乳腺癌的多种生物学和分子通路。此外,我们鉴定出五个RBPs作为乳腺癌的潜在预后生物标志物。我们的研究为在分子水平上理解乳腺癌提供了新的见解。